摘要
目的探讨^(125)I粒子植入联合氩氦刀冷冻消融及康艾注射液治疗中晚期非小细胞肺癌的临床效果。方法回顾性分析河南医学高等专科学校附属医院2014―2019年收治的中晚期非小细胞肺癌患者的临床资料,共入选62例患者,均接受^(125)I粒子植入联合氩氦刀冷冻消融及康艾注射液治疗。参照实体瘤评价标准评价术后1、3、6个月肿瘤客观有效率和疾病控制率。同时评价患者术后2、4周主要症状(咳嗽、咯血、胸闷、胸痛及呼吸困难等缓解情况)。结果术后1、3、6个月客观有效率分别为71.7%、78.3.0%、73.3%,疾病控制率分别为96.7%、91.7%、89.8%,术后2、4周患者咳嗽、咯血、胸闷、胸痛、呼吸困难等均有不同程度缓解。结论^(125)I粒子植入联合氩氦刀冷冻消融及康艾注射液治疗中晚期非小细胞肺癌安全、有效,具有可行性。
Objective To investigate the clinical efficacy of ^(125)I particle implantation combined with cryoablation with argon-helium knife and Kang’ai injection in the treatment of non-small cell lung cancer.Methods Clinical data of patients with advanced non-small cell lung cancer admitted to Affiliated Hospital of Henan Medical College from 2014 to 2019 were retrospectively analyzed.The 62 patients were selected and treated with ^(125)I particle implantation combined with cryoablation with argon-helium knife and Kang’ai injection in the treatment.Objective tumor response rate and disease control rate at 1,3 and 6 months after operation were evaluated according to solid tumor evaluation criteria.Meanwhile,the main symptoms such as cough,hemoptysis,chest tightness,chest pain and dyspnea were evaluated 2 and 4 weeks after surgery.Results The effective rate at 1,3 and 6 months after operation was 71.7%,78.3%and 73.3%,and the disease control rate was 96.7%,91.7%and 89.8%,respectively.The patients had different degrees of relief in cough,hemoptysis,chest distress,chest pain and dyspnea 2 and 4 weeks after operation.Conclusion ^(125)I particle implantation combined with cryoablation with argon-helium knife and Kang’ai injection of non-small cell lung cancer is safe,effective and feasible.
作者
何世阳
葛茂功
叶丰进
付亚杰
张阳
HE Shiyang;GE Maogong;YE Fengjin;FU Yajie;ZHANG Yang(Oncology Department,Affiliated Hospital of Henan Medical College,Zhengzhou 450000,China)
出处
《河南医学研究》
CAS
2022年第21期3864-3867,共4页
Henan Medical Research
基金
河南省医学科技攻关计划(201304080)。
关键词
^(125)I粒子植入
氩氦刀冷冻消融
康艾注射液
中晚期非小细胞肺癌
^(125)I particle implantation
cryoablation with argon-helium knife
Kang’ai injection
advanced non-small cell lung cancer
